Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Ahn MJ, et al. Among authors: gridelli c. Clin Lung Cancer. 2022 Dec;23(8):720-730. doi: 10.1016/j.cllc.2022.07.008. Epub 2022 Jul 21. Clin Lung Cancer. 2022. PMID: 36038416 Free article. Clinical Trial.
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M. Gridelli C, et al. J Thorac Oncol. 2007 Mar;2(3):221-9. doi: 10.1097/JTO.0b013e318031cd62. J Thorac Oncol. 2007. PMID: 17410045 Free article. Clinical Trial.
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, Satta F, Bajetta E, Cortinovis D, Barbieri F, Gebbia V, Grossi F, Novello S, Baldini E, Gasparini G, Latino W, Durante E, Giustini L, Negrini C. Gridelli C, et al. J Thorac Oncol. 2007 Jun;2(6):475-80. doi: 10.1097/01.JTO.0000275342.47584.f3. J Thorac Oncol. 2007. PMID: 17545841 Free article.
Second-line treatment of advanced non-small cell lung cancer.
Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone F, Rosell R, Shepherd FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F. Gridelli C, et al. J Thorac Oncol. 2008 Apr;3(4):430-40. doi: 10.1097/JTO.0b013e318168c815. J Thorac Oncol. 2008. PMID: 18379366 Free article. Clinical Trial.
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial.
Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. Gridelli C, et al. Clin Lung Cancer. 2008 Jul;9(4):235-8. doi: 10.3816/CLC.2008.n.037. Clin Lung Cancer. 2008. PMID: 18650174 Clinical Trial.
New targeted therapies and small-cell lung cancer.
Rossi A, Maione P, Palazzolo G, Sacco PC, Ferrara ML, Falanga M, Gridelli C. Rossi A, et al. Among authors: gridelli c. Clin Lung Cancer. 2008 Sep;9(5):271-9. doi: 10.3816/CLC.2008.n.042. Clin Lung Cancer. 2008. PMID: 18824449 Review.
482 results